The number of patients reporting side effects related to chemotherapy increased by more than 40 percentage points after the implementation of a chemotherapy toxicity screening form.
Cancer Network spoke with Mark H. O’Hara, MD, about the safety and efficacy of APX005M in combination with standard chemotherapy with or without nivolumab.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA
The number of patients reporting side effects related to chemotherapy increased by more than 40 percentage points after the implementation of a chemotherapy toxicity screening form.
A small early-phase trial tested the addition of the oncolytic virus T-VEC to neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Cancer Network spoke with Mark H. O’Hara, MD, about the safety and efficacy of APX005M in combination with standard chemotherapy with or without nivolumab.
